Health-related quality of life in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Post COVID-19 Condition: a systematic review.

Breanna Weigel, Maira Inderyas, Natalie Eaton-Fitch, Kiran Thapaliya, Sonya Marshall-Gradisnik
Author Information
  1. Breanna Weigel: National Centre for Neuroimmunology and Emerging Diseases, Griffith University, 1 Parklands Drive, Southport, Gold Coast, QLD, 4222, Australia. ncned@griffith.edu.au. ORCID
  2. Maira Inderyas: National Centre for Neuroimmunology and Emerging Diseases, Griffith University, 1 Parklands Drive, Southport, Gold Coast, QLD, 4222, Australia. ORCID
  3. Natalie Eaton-Fitch: National Centre for Neuroimmunology and Emerging Diseases, Griffith University, 1 Parklands Drive, Southport, Gold Coast, QLD, 4222, Australia. ORCID
  4. Kiran Thapaliya: National Centre for Neuroimmunology and Emerging Diseases, Griffith University, 1 Parklands Drive, Southport, Gold Coast, QLD, 4222, Australia. ORCID
  5. Sonya Marshall-Gradisnik: National Centre for Neuroimmunology and Emerging Diseases, Griffith University, 1 Parklands Drive, Southport, Gold Coast, QLD, 4222, Australia. ORCID

Abstract

PURPOSE: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Post COVID-19 Condition (PCC) are debilitating, chronic multi-systemic illnesses that require multidisciplinary care. However, people with ME/CFS (pwME/CFS) and people with PCC (pwPCC) are often precluded from accessing necessary disability and social support services. These unmet care needs exacerbate the existing illness burdens experienced by pwME/CFS and pwPCC. To deliver appropriate care and optimise health outcomes for pwME/CFS and pwPCC, the development of evidence-based healthcare policies that recognise the disabling impacts of these illnesses must be prioritised. This systematic review summarises the health-related quality of life (HRQoL) of pwME/CFS and pwPCC when compared with healthy controls (HCs) to elucidate the impacts of these illnesses and guide healthcare policy reform.
METHODS: CINAHL, Embase, MEDLINE, PubMed, PsycINFO and the Web of Science Core Collection were systematically searched from 1st January 2003 to 23rd July 2024. Eligible publications included observational studies capturing quantitative HRQoL data among pwME/CFS or pwPCC when compared with HCs. The use of validated patient-reported outcome measures (PROMs) was mandatory. Eligible studies were also required to employ the most stringent diagnostic criteria currently available, including the Canadian Consensus Criteria or International Consensus Criteria for ME/CFS and the World Health Organization case definition for PCC (PROSPERO ID: CRD42024501309).
RESULTS: This review captured 16 studies, including eight studies among pwME/CFS, seven studies among pwPCC and one study among both illness cohorts. Most participants were female and middle-aged. All pwPCC had experienced prolonged COVID-19 symptoms for at least three months. When compared with HCs, all HRQoL domains were significantly impaired among pwME/CFS and pwPCC. Both illnesses had a salient impact on physical health, including pain and ability to perform daily and work activities. While direct comparisons between pwME/CFS and pwPCC were limited by inconsistencies in the PROMs employed, comparable impact trends across HRQoL domain scores were observed.
CONCLUSION: ME/CFS and PCC have similar, profound impacts on HRQoL that warrant access to multidisciplinary disability and social support services. Future research must harmonise HRQoL data collection and prioritise longitudinal investigations among pwME/CFS and pwPCC to characterise PCC subgroups (including those fulfilling ME/CFS criteria) and predictors of prognosis.

Keywords

References

  1. Int J Equity Health. 2011 Nov 02;10:46 [PMID: 22044797]
  2. Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):E5472-80 [PMID: 27573827]
  3. BMJ Open. 2023 Jun 7;13(6):e069217 [PMID: 37286327]
  4. Nat Commun. 2022 Aug 30;13(1):5104 [PMID: 36042189]
  5. Health Econ. 1993 Oct;2(3):217-27 [PMID: 8275167]
  6. BMJ Open. 2023 Apr 26;13(4):e068481 [PMID: 37185640]
  7. Biomedicines. 2023 Jan 18;11(2): [PMID: 36830795]
  8. Health Qual Life Outcomes. 2014 Apr 30;12:64 [PMID: 24886213]
  9. J Clin Epidemiol. 1998 Nov;51(11):1105-13 [PMID: 9817128]
  10. Front Neurol. 2020 Sep 18;11:1025 [PMID: 33071931]
  11. Front Med (Lausanne). 2023 Jun 02;10:1187163 [PMID: 37342500]
  12. EClinicalMedicine. 2021 Aug;38:101019 [PMID: 34308300]
  13. Clin Microbiol Infect. 2022 Jul;28(7):955-972 [PMID: 35182760]
  14. Diabetes Metab Syndr. 2021 May-Jun;15(3):869-875 [PMID: 33892403]
  15. J Transl Med. 2020 Feb 24;18(1):100 [PMID: 32093722]
  16. BMJ Open. 2024 Jan 17;14(1):e077886 [PMID: 38233057]
  17. Med Care. 1996 Mar;34(3):220-33 [PMID: 8628042]
  18. Science. 2022 Sep 9;377(6611):1150-1151 [PMID: 36074854]
  19. J Adv Res. 2022 Sep;40:179-196 [PMID: 36100326]
  20. Physiother Res Int. 2022 Oct;27(4):e1967 [PMID: 35842844]
  21. PLoS One. 2018 Jun 6;13(6):e0198106 [PMID: 29874259]
  22. Med Clin (Barc). 1998 Oct 10;111(11):410-6 [PMID: 9834913]
  23. Healthcare (Basel). 2021 Sep 29;9(10): [PMID: 34682970]
  24. JAMA. 1989 Aug 18;262(7):925-30 [PMID: 2754793]
  25. BMJ. 2021 Mar 29;372:n71 [PMID: 33782057]
  26. BMC Med Genomics. 2017 Feb 23;10(1):11 [PMID: 28231836]
  27. Ann Clin Transl Neurol. 2024 Feb;11(2):302-320 [PMID: 38130039]
  28. Front Immunol. 2021 Jul 13;12:687806 [PMID: 34326841]
  29. Health Care Women Int. 2014 Jan;35(1):3-26 [PMID: 23445264]
  30. EClinicalMedicine. 2023 Aug 19;63:102146 [PMID: 37662515]
  31. Front Neurol. 2023 Feb 24;14:1090747 [PMID: 36908615]
  32. Spine (Phila Pa 1976). 2000 Dec 15;25(24):3130-9 [PMID: 11124729]
  33. J Magn Reson Imaging. 2016 Nov;44(5):1301-1311 [PMID: 27123773]
  34. Nat Immunol. 2022 Feb;23(2):194-202 [PMID: 35105985]
  35. Medicina (Kaunas). 2021 Apr 26;57(5): [PMID: 33925784]
  36. Int J Environ Res Public Health. 2023 Feb 24;20(5): [PMID: 36901059]
  37. Disabil Rehabil. 2011;33(7):589-98 [PMID: 20617920]
  38. BMC Psychiatry. 2023 Jan 25;23(1):68 [PMID: 36698111]
  39. NMR Biomed. 2011 Dec;24(10):1302-12 [PMID: 21560176]
  40. J Infect Dis. 2022 Nov 1;226(9):1593-1607 [PMID: 35429399]
  41. Qual Life Res. 2024 Sep;33(9):2489-2507 [PMID: 38961009]
  42. Open Forum Infect Dis. 2022 Aug 05;9(8):ofac397 [PMID: 35983269]
  43. J Transl Med. 2023 Nov 1;21(1):775 [PMID: 37915075]
  44. Med Clin (Barc). 1995 May 27;104(20):771-6 [PMID: 7783470]
  45. Chronic Illn. 2022 Dec;18(4):901-910 [PMID: 34541918]
  46. Mayo Clin Proc. 2021 Nov;96(11):2861-2878 [PMID: 34454716]
  47. Front Pediatr. 2019 Feb 05;7:12 [PMID: 30805319]
  48. Nat Med. 2022 May;28(5):911-923 [PMID: 35585196]
  49. Trends Mol Med. 2021 Sep;27(9):895-906 [PMID: 34175230]
  50. Rev Environ Health. 2015;30(4):223-49 [PMID: 26613325]
  51. BMC Med. 2005 Dec 15;3:19 [PMID: 16356178]
  52. Med Care. 1992 Jun;30(6):473-83 [PMID: 1593914]
  53. Mol Med. 2022 Aug 19;28(1):98 [PMID: 35986236]
  54. J Intern Med. 2011 Oct;270(4):327-38 [PMID: 21777306]
  55. Scand J Pain. 2019 Jan 28;19(1):61-72 [PMID: 30325738]
  56. Diabetes Metab Syndr. 2022 Dec;16(12):102660 [PMID: 36351871]
  57. J Transl Med. 2022 Feb 16;20(1):94 [PMID: 35172836]
  58. Sci Rep. 2022 Aug 25;12(1):14505 [PMID: 36008436]
  59. Health Expect. 2024 Feb;27(1):e13900 [PMID: 37905602]
  60. BMC Public Health. 2019 Jun 28;19(1):840 [PMID: 31253111]
  61. Nat Rev Microbiol. 2023 Mar;21(3):133-146 [PMID: 36639608]
  62. BMJ. 2021 Jul 26;374:n1648 [PMID: 34312178]
  63. Soc Sci Med. 2020 Nov;265:113369 [PMID: 33039734]
  64. Public Health Rev. 2022 Mar 15;43:1604501 [PMID: 35359614]
  65. PLoS One. 2023 Feb 16;18(2):e0281884 [PMID: 36795701]
  66. JCI Insight. 2024 Oct 22;9(20): [PMID: 39435656]
  67. Am J Med. 2025 Feb;138(2):354-361.e1 [PMID: 37391116]
  68. Brain Sci. 2023 Dec 01;13(12): [PMID: 38137118]
  69. Emerg Microbes Infect. 2023 Dec;12(2):2220578 [PMID: 37272336]
  70. Front Neurol. 2020 Aug 11;11:826 [PMID: 32849252]

Grants

  1. 489798/Stafford Fox Medical Research Foundation
  2. 1199502/National Health and Medical Research Council
  3. 47107/Mason Foundation
  4. 49979/McCusker Charitable Foundation
  5. 4676/Buxton Foundation
  6. 4879/Henty Community
  7. 4579/Blake Beckett Trust Foundation
  8. 4570/Alison Hunter Memorial Foundation
  9. 4575/Change for ME Charity

MeSH Term

Humans
Fatigue Syndrome, Chronic
Quality of Life
COVID-19
SARS-CoV-2
Female

Word Cloud

Created with Highcharts 10.0.0pwPCCpwME/CFSHRQoLamongME/CFSCOVID-19PCCstudiesillnessesincludingFatigueSyndromePostcareimpactsreviewqualitylifecomparedHCsMyalgicEncephalomyelitis/ChronicConditionmultidisciplinarypeopledisabilitysocialsupportservicesillnessexperiencedhealthhealthcaremustsystematicEligibledataPROMscriteriaConsensusCriteriaimpactHealth-relatedPURPOSE:debilitatingchronicmulti-systemicrequireHoweveroftenprecludedaccessingnecessaryunmetneedsexacerbateexistingburdensdeliverappropriateoptimiseoutcomesdevelopmentevidence-basedpoliciesrecognisedisablingprioritisedsummariseshealth-relatedhealthycontrolselucidateguidepolicyreformMETHODS:CINAHLEmbaseMEDLINEPubMedPsycINFOWebScienceCoreCollectionsystematicallysearched1stJanuary200323rdJuly2024publicationsincludedobservationalcapturingquantitativeusevalidatedpatient-reportedoutcomemeasuresmandatoryalsorequiredemploystringentdiagnosticcurrentlyavailableCanadianInternationalWorldHealthOrganizationcasedefinitionPROSPEROID:CRD42024501309RESULTS:captured16eightsevenonestudycohortsparticipantsfemalemiddle-agedprolongedsymptomsleastthreemonthsdomainssignificantlyimpairedsalientphysicalpainabilityperformdailyworkactivitiesdirectcomparisonslimitedinconsistenciesemployedcomparabletrendsacrossdomainscoresobservedCONCLUSION:similarprofoundwarrantaccessFutureresearchharmonisecollectionprioritiselongitudinalinvestigationscharacterisesubgroupsfulfillingpredictorsprognosisMyalgic Encephalomyelitis/ChronicCondition:LongCOVIDPost-AcuteSequelae

Similar Articles

Cited By